Dr. Abou-Alfa on Trials Investigating Immunotherapy in HCC

Video

In Partnership With:

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses trials investigating immunotherapy in hepatocellular carcinoma (HCC).

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses trials investigating immunotherapy in hepatocellular carcinoma (HCC).

The field of immunotherapy is moving very rapidly based on solid data, explains Abou-Alfa. Preclinical data demonstrate that evidence is there regarding PD-1/PD-L1 expression as well as other markers for checkpoint inhibitors.

The CheckMate-040 trial, which is investigating nivolumab (Opdivo) in patients with HCC, demonstrated that nearly 260 patients had a continued response rate of 20%.

Related Videos
Scott Kopetz, MD, PhD, FACP
Katharina Hoebel, MD, PhD
Catherine C. Coombs, MD, associate clinical professor, medicine, University of California, Irvine School of Medicine
Naomi Adjei, MD, MPH, MSEd, gynecologic oncology fellow, The University of Texas MD Anderson Cancer Center
John M. Kirkwood, MD, Distinguished Service Professor of Medicine, Sandra and Thomas Usher Professor of Medicine, Dermatology & Translational Science, coleader, Melanoma and Skin Cancer Program, Division of Hematology/Oncology, the University of Pittsburgh
Nizar M. Tannir, MD, FACP, professor; Ransom Horne, Jr. Professor for Cancer Research, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
William B. Pearse, MD
Daniel Olson, MD
Nan Chen, MD
Robert Dreicer, MD, director, Solid Tumor Oncology, Division of Hematology/Oncology, professor of Medicine and Urology, deputy director, University of Virginia Cancer Center
Related Content
André Galarneau, PhD

First-Line Pembrolizumab Plus Chemo Wins Canadian Approval for HER2– Advanced Gastric/GEJ Adenocarcinoma

April 19th 2024
Article
Saad Z. Usmani, MD, MBA, FACP

Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

September 4th 2023
Podcast
Elizabeth Plimack, MD, MS, FASCO

Immunotherapy-Based Approaches Make Waves in Bladder Cancer

April 17th 2024
Article
Gina Z. D’Amato, MD

D'Amato Discusses Research and Resistance Mechanisms in Sarcoma and Gastrointestinal Stromal Tumor

February 9th 2023
Podcast
Matthew Galsky, MD

Adjuvant Nivolumab Provides Sustained DFS Benefit, Favors OS in Muscle-Invasive Urothelial Cancer

April 16th 2024
Article
Do-Youn Oh, MD, PhD, professor, Division of Medical Oncology, Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine

Durvalumab Plus Chemo Sustains 3-Year OS Benefit in Advanced Biliary Tract Cancer

April 16th 2024
Article